C12N 9/6472
Cysteine endopeptidases
Official title: {Cysteine endopeptidases (3.4.22)}
C12N9/6472 (Cysteine endopeptidases) appears on 402 US grants and 516 published applications in this corpus.
Search patents in C12N- Granted patents
- 402
- Published applications
- 516
- Assignees
- 300
- Inventors
- 1,074
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 1 | 0 |
| 1996 | 5 | 0 |
| 1997 | 5 | 0 |
| 1998 | 18 | 0 |
| 1999 | 26 | 0 |
| 2000 | 28 | 0 |
| 2001 | 39 | 2 |
| 2002 | 28 | 52 |
| 2003 | 32 | 56 |
| 2004 | 24 | 33 |
| 2005 | 12 | 18 |
| 2006 | 19 | 29 |
| 2007 | 18 | 19 |
| 2008 | 13 | 9 |
| 2009 | 6 | 22 |
| 2010 | 6 | 11 |
| 2011 | 5 | 6 |
| 2012 | 7 | 7 |
| 2013 | 2 | 9 |
| 2014 | 5 | 9 |
| 2015 | 6 | 19 |
| 2016 | 5 | 14 |
| 2017 | 6 | 13 |
| 2018 | 7 | 12 |
| 2019 | 11 | 22 |
| 2020 | 5 | 19 |
| 2021 | 14 | 22 |
| 2022 | 10 | 23 |
| 2023 | 10 | 14 |
| 2024 | 10 | 33 |
| 2025 | 10 | 22 |
| 2026 | 4 | 21 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Engineered cells and uses thereof6 Oct 2026US 12,751,929 B2Ohio State Innovation Foundation
- TEV protease with dual affinity tags19 May 2026US 12,630,813 B2AbClonal Science, Inc.
- Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes24 Feb 2026US 12,559,739 B2The Trustees of Columbia University in the City of New York
- DNA, expression vector, transcript, cell, pharmaceutical composition, and medicine13 Jan 2026US 12,521,450 B2Hitachi, Ltd.
- Leucine zipper-based compositions and methods of use30 Dec 2025US 12,509,498 B2Memorial Sloan Kettering Cancer Center
- Non-human animal, kit, and method for producing replacement organ24 Sep 2026US 2026/0283124 A1The Jikei University
- Regulated cells expressing cytokines24 Sep 2026US 2026/0286288 A1
- Site-specific orthogonal bioconjugate modality and application thereof24 Sep 2026US 2026/0286332 A1Genequantum Healthcare (Suzhou) Co., Ltd.
- Cd79b humanized antibody-based chimeric antigen receptor and use thereof20 Aug 2026US 2026/0241000 A1Beijing Meikang Geno-Immune Biotechnology Co., Ltd.
- Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes13 Aug 2026US 2026/0234594 A1The Trustees of Columbia University in the City of New York
Most cited
By later US patents
- Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy129US 6,348,185 B1Washington University School of Medicine · 2002
- Methods for correcting presenilin point mutations123US 9,068,179 B1President and Fellows of Harvard College · 2015
- Methods for nucleic acid editing121US 9,840,699 B2President and Fellows of Harvard College · 2017
- Compositions and methods for the treatment and diagnosis of immune disorders111US 6,562,343 B1Millennium Pharmaceuticals, Inc. · 2003
- Compositions and methods for the treatment and diagnosis of immune disorders106US 6,414,117 B1Millennium Pharmaceuticals, Inc. · 2002